Key facts
- Reme-D’s last known valuation is $330K (May 2024).
- It has raised $520K; the latest was Early Stage VC ($500K) in Apr 2026.
- Notable investors include Techstars, Mohammed Bin Rashid Innovation Fund, African Union Development Agency-NEPAD, A15, Global Innovation Fund — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Reme-D
- ·The full record, as it builds
Funding rounds
No funding rounds for Reme-D are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reme-D
Provider of molecular diagnostic kits intended to enhance the accuracy and timeliness of disease detection. The company's technology facilitates precise and efficient nucleic acid extraction and advanced techniques for amplification and detection, incorporating features such as shorter and simpler testing protocols with increased stability in hot and humid climates, enabling global populations in underserved areas to access accurate and reliable diagnostics and treatment information.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 32
- Website
- reme-d-inc.com/
- Ownership
- Privately Held (backing)
Reme-D doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reme-D shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reme-D in its N-PORT filings yet. We sweep new filings monthly.